首页 > 文章详情

【必看】2018ASCO最重要4项研究是什么？

2018年04月28日

编译：肿瘤资讯-小编

来源：肿瘤资讯

2018ASCO大会马上就要来！本次大会上最重要的研究是什么呢？请关注6月3日下午的全体大会。

微信图片_20180428114105.jpg

Abstract LBA1

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

TAILORx：化疗+内分泌治疗与内分泌治疗单独治疗激素受体阳性，HER2阴性，淋巴结阴性和21-基因复发评分为中等预后的乳腺癌的III期试验。

Joseph A. Sparano, MD - First Author

Montefiore Medical Center

Abstract LBA2

2:10 PM - 2:25 PM

Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

维持低剂量化疗（RMS）治疗高风险（HR）横纹肌肉瘤患者，来自欧洲儿科软组织肉瘤研究组（EpSSG）的研究报告。

Gianni Bisogno, MD - First Author

Department of Women and Children Health, University Hospital of Padova

Abstract LBA3

2:40 PM - 2:55 PM

CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

CARMENA：在转移性肾细胞癌中接受减瘤肾切除术+舒尼替尼和单用舒尼替尼 III期非劣效性试验的结果。

Arnaud Mejean, MD, PhD - First Author

Department of Urology，Hôpital Européen Georges-Pompidou - Paris Descartes University

Abstract LBA4

3:10 PM - 3:25 PM

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

Pembrolizumab（pembro）与含铂化疗作为PD-L1（TPS）≥1％的晚期/转移性NSCLC的一线治疗研究结果：开放标签第3期KEYNOTE-042研究。

Gilberto Lopes, MD, MBA - First Author

Sylvester Comprehensive Cancer Center, University of Miami Health System